912 related articles for article (PubMed ID: 25975191)
1. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
3. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
[TBL] [Abstract][Full Text] [Related]
6. Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.
Mustafa N; Nee AHF; Chooi JY; Toh SHM; Chung TH; Selvarajan V; Fan S; Ng SB; Poon M; Chan E; Lee J; Chee YL; Jeyasekharan AD; Zhou L; Yang J; Chng WJ
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215687
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Xia C; Ribeiro M; Scott S; Lonial S
Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
[TBL] [Abstract][Full Text] [Related]
8. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma.
Nakamura A; Suzuki S; Kanasugi J; Ejiri M; Hanamura I; Ueda R; Seto M; Takami A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639102
[TBL] [Abstract][Full Text] [Related]
10. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
11. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.
Naeimi Kararoudi M; Nagai Y; Elmas E; de Souza Fernandes Pereira M; Ali SA; Imus PH; Wethington D; Borrello IM; Lee DA; Ghiaur G
Blood; 2020 Nov; 136(21):2416-2427. PubMed ID: 32603414
[TBL] [Abstract][Full Text] [Related]
12. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.
Lejeune M; Duray E; Peipp M; Clémenceau B; Baron F; Beguin Y; Caers J
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203012
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
14. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
Shrestha P; Astter Y; Davis DA; Zhou T; Yuan CM; Ramaswami R; Wang HW; Lurain K; Yarchoan R
Oncoimmunology; 2023; 12(1):2163784. PubMed ID: 36632565
[TBL] [Abstract][Full Text] [Related]
16. Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
Ise M; Matsubayashi K; Tsujimura H; Kumagai K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e59-64. PubMed ID: 26997107
[No Abstract] [Full Text] [Related]
17. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Plesner T; van de Donk N; Richardson PG
Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
[TBL] [Abstract][Full Text] [Related]
18. The CD38
Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L; Wang Y; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
